TY - JOUR T1 - Cannabinoid Receptor Type 1 (CB1) Antagonist, SR141716 Suppresses Hepatic CPT1 Gene Expression in Rat AU - Wang, Yizhen AU - Zhu, Linna AU - Yu, Xiufeng AU - Wu, Ting JO - Journal of Animal and Veterinary Advances VL - 11 IS - 16 SP - 2969 EP - 2975 PY - 2012 DA - 2001/08/19 SN - 1680-5593 DO - javaa.2012.2969.2975 UR - https://makhillpublications.co/view-article.php?doi=javaa.2012.2969.2975 KW - high fat diet KW -mRNA level KW -CB1 KW -CPT1 KW -body weight KW -hepatic fat deposition KW -visceral fat deposition KW -antagonist KW -SR141716 KW -rat AB - SR141716 is the antagonist of Cannabinoid Receptor type 1 (CB1). The study was conducted to investigate the effects of SR141716 on body weight gain, body fat, hepatic fat deposit and Carnitine Palmitoyltransferase 1 (CPT1) expression in obese Sprague-Dawley (SD) rats induced by High Fat Diet (HFD). Twenty four SD rats were randomly allocated to three groups: the Normal Diet (ND) as control group, the High Fat Diet (HFD) and SR141716 treated HFD-diet (SFD) animals as experimental groups. Plasma was collected immediately for following plasma indexes determination. Liver samples were flash frozen in lipid nitrogen and stored at –80°C until use for following experiments. Compared with the ND group, HFD significantly increased the body weight gain (p<0.05), total viscera fat pad (p<0.05) and hepatic Triglyceride (TG) (p<0.05) in rats while SR141716 significantly suppressed these effects (p<0.05). Furthermore, hepatic CPT1 mRNA level was significant decreased by HFD (p<0.05). Hepatic CPT1 and PPARγ mRNA level were significantly suppressed by SR141716 accompany with CB1 mRNA expression decrease (p<0.05). The results indicated that SR141716 can significantly suppress the excess hepatic adipose deposit induced by HFD in rats. During this process, the pivotal role of CB1 in hepatic fat deposit may considerably to a large extent be due to modulation of CPT1 expression through PPARγ. However, the accurate mechanism remains to be elucidated in the future. ER -